A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors

被引：0
|
作者：
Shigehisa Kitano
Yutaka Fujiwara
Toshio Shimizu
Satoru Iwasa
Kan Yonemori
Shunsuke Kondo
Akihiko Shimomura
Takafumi Koyama
Takahiro Ebata
Hiroki Ikezawa
Nozomi Hayata
Yukinori Minoshima
Takuma Miura
Tomoki Kubota
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital,Department of Experimental Therapeutics
[2] The Cancer Institute Hospital of JFCR,Department of Advanced Medical Development
[3] Aichi Cancer Center,Department of Thoracic Oncology
[4] National Center for Global Health and Medicine,Department of Breast and Medical Oncology
[5] Eisai Co.,Clinical Data Science Department
[6] Ltd,Clinical Pharmacology Science Department
[7] Eisai Co.,Japan and Asia Clinical Development Department
[8] Ltd,undefined
[9] Tsukuba Research Laboratories,undefined
[10] Eisai Co.,undefined
[11] Ltd,undefined
[12] Eisai Co.,undefined
[13] Ltd,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 90卷
关键词：
Biomarkers; Lenvatinib; Pembrolizumab; Pharmacokinetics; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：523 / 529
页数：6
相关论文
共 50 条
  • [31] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Ged, Yasser
    Lee, Chung-Han
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
  • [32] LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
    Lwin, Z.
    Gomez-Roca, C.
    Saada-Bouzid, E.
    Yanez, E.
    Longo Munoz, F.
    Im, S-A.
    Castanon, E.
    Senellart, H.
    Graham, D.
    Voss, M.
    Doherty, M.
    Lopez, J.
    Ghori, R.
    Kubiak, P.
    Jin, F.
    Norwood, K.
    Chung, H. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1170 - S1170
  • [33] Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
    Strosberg, J.
    Al-Toubah, T.
    Morse, B.
    Haider, M.
    Valone, T.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 237 - 237
  • [34] Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
    Al-Toubah, T.
    Schell, M. J.
    Morse, B.
    Haider, M.
    Valone, T.
    Strosberg, J.
    ESMO OPEN, 2024, 9 (04)
  • [35] Lenvatinib plus pembrolizumab requires monitoring in patients with aRCC
    Reactions Weekly, 2023, 1947 (1) : 12 - 12
  • [36] Lenvatinib plus pembrolizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma: A real world study.
    Lee, I-Cheng
    Wu, Chi-Jung
    Chen, San-Chi
    Chao, Yee
    Huang, Yi-Hsiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort
    Chung, H.
    Villanueva, L.
    Graham, D.
    Saada-Bouzid, E.
    Ghori, R.
    Kubiak, P.
    Gumuscu, B.
    Lerman, N.
    Gomez-Roca, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S146 - S146
  • [38] Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Ikeda, Masafumi
    Zhu, Andrew X.
    Sung, Max W.
    Baron, Ari D.
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Shuichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Kubota, Tomoki
    Dutcus, Corina E.
    Saito, Kenichi
    Siegel, Abby B.
    Dubrovsky, Leonid
    Mody, Kalgi
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) : 2960 - +
  • [39] Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors
    Liu, Dan
    Liu, Lei
    Shen, Lin
    Kubota, Tomoki
    Suzuki, Takuya
    Ikezawa, Hiroki
    Shiba, Sari
    Bai, Yuxian
    FUTURE ONCOLOGY, 2021, 17 (15) : 1855 - 1863
  • [40] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
12345